Sudarshan Pharma Industries Limited (BOM:543828)
India · Delayed Price · Currency is INR 35.60
-0.71 (-1.96%)
At close: Aug 17, 2026
BOM:543828 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 7,322 | 7,031 | 5,050 | 4,635 | 4,613 | 3,571 |
Other Revenue | 0.13 | - | - | - | - | - |
| 7,322 | 7,031 | 5,050 | 4,635 | 4,613 | 3,571 | |
Revenue Growth | 32.86% | 39.21% | 8.95% | 0.48% | 29.19% | 84.52% |
Cost of Revenue | 6,399 | 6,194 | 4,398 | 4,226 | 4,310 | 3,354 |
Gross Profit | 923.16 | 836.79 | 652.05 | 409.86 | 303.72 | 217.06 |
Selling, General & Admin | 79.21 | 74.37 | 70.27 | 47.49 | 41.93 | 30.82 |
Other Operating Expenses | 282.11 | 249.26 | 175.32 | 125.44 | 109.59 | 76.08 |
Operating Expenses | 404.43 | 361.52 | 267.8 | 185.38 | 160.59 | 115.56 |
Operating Income | 518.73 | 475.27 | 384.25 | 224.48 | 143.12 | 101.5 |
Interest Expense | -279.5 | -257.01 | -141.04 | -78.7 | -45.86 | -27.58 |
Interest & Investment Income | - | - | 5.55 | 7.88 | 4.9 | 1.99 |
Currency Exchange Gain (Loss) | - | - | 2.01 | 1.95 | 0.13 | 0.11 |
Other Non Operating Income (Expenses) | 87.13 | 87.13 | -6.3 | -3.33 | -4.95 | -3.67 |
EBT Excluding Unusual Items | 326.36 | 305.4 | 244.47 | 152.28 | 97.34 | 72.35 |
Gain (Loss) on Sale of Assets | - | - | - | - | -2.37 | -0.99 |
Other Unusual Items | - | - | -28.17 | - | - | - |
Pretax Income | 326.36 | 305.4 | 216.29 | 152.28 | 94.96 | 71.36 |
Income Tax Expense | 76.13 | 71.68 | 56.77 | 37.73 | 24.6 | 18.87 |
Earnings From Continuing Operations | 250.23 | 233.72 | 159.53 | 114.55 | 70.37 | 52.49 |
Minority Interest in Earnings | 0.99 | -0.68 | 0.02 | - | - | -0.01 |
Net Income | 251.22 | 233.03 | 159.55 | 114.55 | 70.37 | 52.48 |
Net Income to Common | 251.22 | 233.03 | 159.55 | 114.55 | 70.37 | 52.48 |
Net Income Growth | 18.94% | 46.05% | 39.28% | 62.79% | 34.09% | 96.46% |
Shares Outstanding (Basic) | 241 | 240 | 242 | 239 | 241 | 144 |
Shares Outstanding (Diluted) | 241 | 240 | 242 | 239 | 241 | 144 |
Shares Change | -0.99% | -0.62% | 1.30% | -0.83% | 66.88% | -5.63% |
EPS (Basic) | 1.04 | 0.97 | 0.66 | 0.48 | 0.29 | 0.36 |
EPS (Diluted) | 1.04 | 0.97 | 0.66 | 0.48 | 0.29 | 0.36 |
EPS Growth | 20.14% | 46.97% | 37.50% | 64.16% | -19.65% | 108.19% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -713.96 | 302.13 | 59.02 | -431.2 | -54.79 |
Free Cash Flow Per Share | - | -2.97 | 1.25 | 0.25 | -1.79 | -0.38 |
Dividend Per Share | - | - | - | - | 0.030 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 12.61% | 11.90% | 12.91% | 8.84% | 6.58% | 6.08% |
Operating Margin | 7.08% | 6.76% | 7.61% | 4.84% | 3.10% | 2.84% |
Profit Margin | 3.43% | 3.31% | 3.16% | 2.47% | 1.52% | 1.47% |
Free Cash Flow Margin | - | -10.15% | 5.98% | 1.27% | -9.35% | -1.53% |
EBITDA | 563.51 | 513.16 | 394.55 | 236.77 | 152.19 | 110.15 |
EBITDA Margin | 7.70% | 7.30% | 7.81% | 5.11% | 3.30% | 3.08% |
D&A For EBITDA | 44.78 | 37.88 | 10.3 | 12.29 | 9.07 | 8.66 |
EBIT | 518.73 | 475.27 | 384.25 | 224.48 | 143.12 | 101.5 |
EBIT Margin | 7.08% | 6.76% | 7.61% | 4.84% | 3.10% | 2.84% |
Effective Tax Rate | 23.33% | 23.47% | 26.24% | 24.78% | 25.90% | 26.45% |
Revenue as Reported | 7,409 | 7,118 | - | 4,661 | 4,624 | 3,576 |
Advertising Expenses | - | - | 0.21 | 0.28 | 0.07 | 0.04 |